Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
US8367062B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2009 |
| Grant date | Feb 5, 2013 |
| Priority date | — |
| Expiry date | Jan 26, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Glycopeptide comprising 1 to 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby said polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes and/or purified from biological fluids of human or animal origin or recombinant and produced by expression in a standard host cell comprising an enzymatic material necessary for priming a glycosylation, said host cell being genetically modified such as to comprise a gene coding for said polypeptides and a gene coding for one or more enzymes selected from among glycosyltransferases, anti-glycopeptide antibodies and the applications thereof in therapeutics and diagnostics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.